Search Results - "Rothenstein, Jeffrey M"

Company Stock Prices Before and After Public Announcements Related to Oncology Drugs by Rothenstein, Jeffrey M., Tomlinson, George, Tannock, Ian F., Detsky, Allan S.

“…Background Phase III clinical trials and Food and Drug Administration (FDA) regulatory decisions are critical for success of new drugs and can influence a…”
Get full text

Non-malignant and tumor-derived cells differ in their requirement for p27Kip1 in transforming growth factor-beta-mediated G1 arrest by Donovan, Jeffrey C H, Rothenstein, Jeffrey M, Slingerland, Joyce M

“…Transforming growth factor beta (TGF-beta) induces G(1) arrest in susceptible cells by multiple mechanisms that inhibit the G(1) cyclin-dependent kinases…”
Get full text

ALK inhibitors, resistance development, clinical trials by Rothenstein, J M, Chooback, N

“…The treatment of advanced non-small-cell lung cancer (nsclc) has undergone a paradigm shift since the early 2000s. The identification of molecular subtypes of…”
Get full text

Managing treatment-related adverse events associated with Alk inhibitors by Rothenstein, J M, Letarte, N

“…Anaplastic lymphoma kinase (ALK) rearrangements have been identified as key oncogenic drivers in a small subset of non-small-cell lung cancers (nsclcs)…”
Get full text

The Perceived Value of Liquid Biopsy: Results From a Canadian Validation Study of Circulating Tumor DNA T790M Testing—Patient’s Willingness-to-Pay: A Brief Report by Chen, Kaitlin H., Barnes, Tristan A., Laskin, Janessa, Cheema, Parneet, Liu, Geoffrey, Iqbal, Mussawar, Rothenstein, Jeffrey, Burkes, Ronald, Tsao, Ming-Sound, Leighl, Natasha B.

“…Liquid biopsy is recommended to diagnose molecular resistance to targeted therapy in patients with lung cancer. Nevertheless, not all jurisdictions provide…”
Get full text

Non-malignant and Tumor-derived Cells Differ in Their Requirement for p27Kip1 in Transforming Growth Factor-β-mediated G1 Arrest by Jeffrey C. H. Donovan, Jeffrey M. Rothenstein, Joyce M. Slingerland

“…Transforming growth factor β (TGF-β) induces G 1 arrest in susceptible cells by multiple mechanisms that inhibit the G 1 cyclin-dependent kinases (Cdks),…”
Get full text